These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10753829)

  • 1. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.
    Harker LA; Roskos LK; Marzec UM; Carter RA; Cherry JK; Sundell B; Cheung EN; Terry D; Sheridan W
    Blood; 2000 Apr; 95(8):2514-22. PubMed ID: 10753829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.
    Harker LA; Hunt P; Marzec UM; Kelly AB; Tomer A; Hanson SR; Stead RB
    Blood; 1996 Mar; 87(5):1833-44. PubMed ID: 8634430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
    J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
    Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
    Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
    O'Malley CJ; Rasko JE; Basser RL; McGrath KM; Cebon J; Grigg AP; Hopkins W; Cohen B; O'Byrne J; Green MD; Fox RM; Berndt MC; Begley CG
    Blood; 1996 Nov; 88(9):3288-98. PubMed ID: 8896392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
    Harker LA; Marzec UM; Novembre F; Sundell IB; Waller EK; Karpatkin S; McClure HM; Kelly AB; Stead RB
    Blood; 1998 Jun; 91(12):4427-33. PubMed ID: 9616135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
    Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
    Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
    Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.
    Snyder E; Perrotta P; Rinder H; Baril L; Nichol J; Gilligan D
    Transfusion; 1999 Mar; 39(3):258-64. PubMed ID: 10204587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
    Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
    Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
    Kuter DJ; Goodnough LT; Romo J; DiPersio J; Peterson R; Tomita D; Sheridan W; McCullough J
    Blood; 2001 Sep; 98(5):1339-45. PubMed ID: 11520780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
    Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
    Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
    Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
    Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model.
    Nishiyama U; Kuwaki T; Akahori H; Kato T; Ikeda Y; Miyazaki H
    J Thromb Haemost; 2005 Feb; 3(2):355-60. PubMed ID: 15670044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.